PerkinElmer and Scitara join forces to create tech-driven ‘model of the modern lab’

Both companies will integrate their products to improve data management and automation in a laboratory setting
Analytical technology leader PerkinElmer and cloud-based software provider Scitara have announced a collaboration that combines their product offerings to create a ‘model of the modern lab’.
The move will see PerkinElmer integrate its Signals Research Suite informatics platform with Scitara’s Scientific Integration Platform (SIP) to create a fully connected laboratory with enhanced data management and automation capabilities.
PerkinElmer’s Signals Research Suite provides end-to-end scientific data and workflow management, while Scitara’s SIP provides a universal connectivity solution in a cloud native infrastructure. The deal aligns with PerkinElmer’s strategy of using its informatics offerings to drive digital transformation in the lab.
Scitara’s CEO Ajit Nagral said the agile framework offered by the collaboration guarantees flexibility as standard.
‘It provides the ability to extract maximum value from legacy equipment, while dramatically lowering the barrier to introduce new, innovative technology into the connected lab. We drive data aggregation to any selected customer repository in an agile, compliant and future-proof solution.
A breakthrough level of automation – from the simplest to the most complex tasks – is achieved while complying with the most stringent requirements of regulated markets,' he said.
Earlier this year Scitara raised $15 million in Series B funding, which analysts say was fuelled by the success of its SIP.
Speaking about the collaboration, Kevin Willoe, VP and General Manager, Informatics at PerkinElmer, said merging the two services will create a ‘truly integrated laboratory environment.’
‘This will help tie together instruments, software and systems and support our customers in curating data in a standardized platform. This is the power of the lab of the future in action,’ he said.
Both companies say integrating the SIP infrastructure with the PerkinElmer Signals Research platform will allow for improved data management, enhanced collaboration and more lab automation. Integrated data science can be used in tandem with AI and analytic tools, providing scientists with faster insights, fuelling decision making and ultimately accelerating products to market.
Related News
-
News Your Prescription for Marketing Success: Digital Pharma Marketing Toolkit – Free eBook
Download your FREE pharma marketing eBook to learn why it is so important for pharmaceutical marketeers to develop their digital content marketing strategies in order to establish their companies as thought leaders and industry experts. -
News 3 ways ChatGPT will impact pharma marketing teams
What does the rise of AI-powered chatbots such as ChatGPT and GPT-4 mean for pharma marketeers? -
News Pharma needs ‘mindset change’ to unlock benefits of digitalisation – CPHI Frankfurt preview
For more information about digitalisation in pharma, register to attend CPHI Frankfurt 2022. -
News TraceLink to launch AI solution for predicting drug shortages
TraceLink’s Product Availability Intelligence will enable stakeholders to predict drug shortages months in advance -
News Pharmapack 2021: Increasing connectivity is the key to patient centricity and simplified access to product information
During the live Innovation in Connectivity Roundtable at the Pharmapack 2021 online conference, experts discussed how the latest innovations in digital technology are shaping industry ambitions to put the patient journey at the heart of its drug device... -
News Advanced Computing in Pharma: 3 reasons why quantum computing could disrupt R&D
Quantum computing technology uses quantum systems called “qubits”. They work with non-binary values, unlike classical computing which uses only bits with values of 0 or 1, and can overlap each other and act as a group. The result is a ... -
News 5 Strategies for Engaging a Pharma Audience All Year Round
For pharma manufacturers and service providers, attending face-to-face events and exhibitions has always been a crucial tool for meeting existing clients, signing contracts, and gathering leads for new business. But with events unable to trade over the... -
News Artificial intelligence a no-brainer for drug discovery
AI is helping pharma find the drug candidates with the greatest chance of success, according to experts who say therapeutic efficacy and cost reduction are the key dynamics
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance